Home > Faculty and Staff > M-Z > Joel Slaton, MD
Joel Slaton, MD
Position: Associate Professor
Organization: Department of Urologic Surgery
Office Address
D-596 Mayo
420 Delaware St SE
Minneapolis, MN 55455
Home Address
3806 West 32nd Street
Minneapolis, MN 55416
Office Phone: 612-625-2667
Home Phone: 612-925-6278
Pager: 612-899-7770
Mobile Phone: <Information Not Provided>
Email Address: slato001@umn.edu
Educational Background
Vanderbilt University - BS 1984
Vanderbilt University - MD 1988
Brief Biography
Dr. Slaton is an Associate Professor in the Department of Urologic Surgery.
He is Director of Research for both the Department of Urologic Surgery and the Center for Spirituality & Healing.
Teaching Areas
Teaching residents
Research Interests
Study of botanical with a focus on mushrooms. He is the PI for the NIH- funded Developmental Center for Research in CAM.
Selected Publications
1. Inoue, K., Slaton, J.W., Perrotte, P., Davis, D.W., Bruns, C. J., Hicklin, D.J., McConkey, D., Radinsky, R. and Dinney, C.P.N Paclitaxel enhances the effects of the anti-epidermal growth factor receptor Imclone C225 in mice with metastatic human bladder transitional cell carcinoma Clin Cancer Res. 6:4874-84, 2000.
2. Inoue K, Slaton J.W., Karashima T, Yoshikawa C, Shuin T, Sweeney P, Millikan R, Dinney CP. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res. 6:4866-73, 2000
3. Slaton JW, Inoue K, Perrotte P, El-Naggar AK, Swanson DA, Fidler IJ, Dinney CP. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol.158:735-743, 2001
4. Slaton, J.W., Morganstern, N., Levy, D.A., Ayala, A., Santos, M.W., and Pettaway, C.A., Vascular invasion and tumor stage are independent prognosticators of lymph node metastasis in squamous penile cancer. J Urol 165:1138-42,2001.
5. Inoue K, Wood CG, Slaton JW, Karashima T, Sweeney P, Dinney CP. Adenoviral-mediated gene therapy of human bladder cancer with antisense interleukin-8. Oncol Rep. 8:955-64, 2001.
6. Slaton JW, Karashima T, Perrotte P, Inoue K, Kim SJ, Izawa J, Kedar D, McConkey DJ, Millikan R, Sweeney P, Yoshikawa C, Shuin T, Dinney CP.Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. Clin Cancer Res.7:2840, 2001.
7. Mian BM, Bhadkamkar N, Slaton JW, Pisters PW, Daliani D, Swanson DA, Pisters LL. Prognostic factors and survival of patients with sarcomatoid renal cell carcinoma. J Urol. 2002 Jan;167(1):65-70.
8. Izawa JI, Sweeney P, Perrotte P, Kedar D, Dong Z, Slaton JW, Karashima T, Inoue K, Benedict WF, Dinney CP. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.Clin Cancer Res. 2002 Apr;8(4):1258-70.
9. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 2002 May;8(5):1253-6.
10. Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CP, Shuin T. The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res. 2002 Jun;8(6):1863-70.
11. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T,
Dinney CP. Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res. 2002 May;8(5):1253-64.
12. Pagliaro LC, Keyhani A, Williams D, Woods D, Liu B, Perrotte P, Slaton JW, Merritt JA, Grossman HB, Dinney CP. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003, Jun 15;21(12):2247-53.
13. Sweeney P, Wood CG, Pisters LL, Slaton JW, Vaporciyan A, Munsell M, Carpenter S, Putnam J, Swisher SG, Walsh G, Swanson D, Dinney CP. Surgical management of renal cell carcinoma associated with complex inferior vena caval thrombi. Urol Oncol. 2003 Sep-Oct;21(5):327-33.
14. Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology. 2004 Jan;63(1):46-50.
15. Slaton JW, Millikan R, Inoue K, Karashima T, Czerniak B, Shen Y, Yang Y, Benedict WF, Dinney CP. Correlation of metastasis related gene expression and relapse-free survival in patients with locally advanced bladder cancer treated with cystectomy and chemotherapy. J Urol. 2004 Feb;171(2 Pt 1):570-4.
16. Unger GM, Davis AT, Slaton JW, Ahmed K. Protein kinase CK2 as regulator of cell survival: implications for cancer therapy. Curr Cancer Drug Targets. 2004 Feb;4(1):77-84
17. Naya Y, Slaton JW, Troncoso P, Okihara K, Babaian RJ. Tumor length and location of cancer on biopsy predict for side specific extraprostatic cancer extension. J Urol. 2004 Mar;171(3):1093-7.
18. Slaton JW, Unger GM, Sloper DT, Davis AT, Ahmed K. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res. 2004 Dec;2(12):712-21.
19. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K. Downregulation of CK2 induces apoptosis in cancer cells--a potential approach to cancer therapy. Mol Cell Biochem. 2005 Jun;274(1-2):77-84.
20. Wilson MJ, Haller R, Li SY, Slaton JW, Sinha AA, Wasserman NF. Elevation of dipeptidylpeptidase iv activities in the prostate peripheral zone and prostatic secretions of men with prostate cancer: possible prostate cancer disease marker. J Urol. 2005 Sep;174(3):1124-8.
21. Canales BK, Anderson JK, Premoli J, Slaton JW. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer. J Urol. 2006 Jan;175(1):74-7.
22. Wang G, Ahmad KA, Unger G, Slaton JW, Ahmed K. CK2 signaling in androgen-dependent and -independent prostate cancer. J Cell Biochem. 2006 Oct 1;99(2):382-91.
|
Return to: Academic Health Center : myU : U of M Home
